ALSO NOTED: FDA: New Zyprexa sedates some;Vanderbilt outlaws rep freebies;

> Prepping for advisory panel review, FDA staff says long-lasting Zyprexa causes drowsiness. Report

> Vanderbilt Medical Center has become the latest hospital to ban gifts from drug reps as part of a new conflict-of-interest policy. Report

> European regulators gave the nod to Roche's chemotherapy drug Xeloda for use against metastatic colorectal cancer in combo with other chemo meds. Report

> U.K. doctors called on the National Health Service to share more information about its dealings with the pharmaceutical industry. Report

> Bayer CEO Werner Wenning says the company has plenty of cash to make acquisitions even after last year's buyout of German drug maker Schering. Report

> Schering-Plough got the FDA nod for its Asmanex Twisthaler asthma treatment for prevention of symptoms in children 4 to 11 years. Report

> Three more congressmen have joined the fray over Denderon's delayed prostate cancer vaccine Provenge. Report

> Following a label change, Novartis has won EU approval for its trouble diabetes drug Galvus. Report

> Biotech and emerging drug markets are big targets for venture capitalists. Report

And Finally... Could low-salt and high-veggie diets succeed where blood pressure meds fail? Report

Suggested Articles

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.

Both IL-17A inhibitors have rolled out data showing they work in non-radiographic axial spondyloarthritis.